NeuroscienceNeurobiology of DiseasePeer-reviewed
An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease
Britney N. Lizama, H.A. North, K. Pandey…·Madison Hamby
This paper reports exploratory CSF proteomics data from a Phase 2 trial of CT1812 in Alzheimer's disease, identifying pharmacodynamic biomarkers and mechanistic insights.
19 citationstop 3%